Blog

Yüksel Ürün: Did you know the FDA approved cancer drugs target fewer than 200 proteins?

Photo from Yüksel Ürün/X

Jul 1, 2024, 15:09

Yüksel Ürün: Did you know the FDA approved cancer drugs target fewer than 200 proteins?

Yüksel Ürün shared a post on X:

“Did you know the FDA approved cancer drugs target fewer than 200 proteins?

Integrating proteogenomics data from 1,043 patients identified new therapeutic targets.
Analysis of 2,863 druggable proteins revealed key mRNA-protein correlations.
Tumor proteomics and genetic screens uncovered druggable dependencies and synthetic lethality strategies.”

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field. .

biomedical research cancer cancer drugs Cancer research Druggable Proteins FDA Genetic Screens OncoDaily Oncology Precision Medicine proteogenomics Synthetic Lethality therapeutic targets Tumor Proteomics

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage